Journal Information
Vol. 33. Issue. 1.January 2013
Pages 1-154
Share
Share
Download PDF
More article options
Vol. 33. Issue. 1.January 2013
Pages 1-154
Full text access
Response to 'Comment on 'Membranous glomerulonephritis associated with mieloperoxidase antineutrophil cytoplasmic antibody-associated glomerulonephritis''
Visits
6574
Guang-Yu Zhoua, Li-Rong Bib
a Department of Nephrology, China-Japan Union Hospital of Jilin University, Changchun, Jilin Province, China,
b Department of Pathology, First Hospital of Jilin University, Changchun, Jilin Province, China,
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text

Dear Editor,

We were very interested by the comment submitted by Dr. Gioacchino Li Cavoli and his collaborators, regarding their similar experience of a membranous glomerulonephritis with crescentic overlap. First of all, we would like to thank them for their input.

They reported a case of membranous glomerulonephritis (MGN) with crescentic transformation in a ANCA-negative vasculitis which revealed no evidence of systemic lupus erythematosus (SLE), anti-glomerular basement membrane (GBM) glomerulonephritis, infection, malignancy and showed no improvement after immunosuppressive treatments. The case they presented was similar to the patient that Kwan JT et al. described previously.1 Although several authors have demonstrated the concomitance of MGN and ANCA-associated glomerulonephritis,2-6 MGN accompanied by ANCA-negative crescentic glomerulonephritis has been rarely encountered.

The light microscopic visualization of renal tissue in their case showed the formation of 11 crescents (3 cellular crescents, 1 fibrocellular crescent and 7 fibrotic crescents) and 11 out of 17 glomeruli were globally sclerotic. These histopathological changes indicate the patient has reached to an advanced stage of crescentic glomerulonephritis and the renal disease has progressed to the sclerotic phase at the time of renal biopsy. Nasr SH et al. reported that the percentage of globally sclerotic glomeruli correlated with nonresponse to immunosuppressive agents.5 This is why the patient showed no improvement after treated with steroid plus cyclophosphamide and started chronic haemodialysis treatment eventually. By contrast, our case showed 2 sclerosed glomeruli out of 19 glomeruli, the formation of 9 crescents including 4 cellular crescents and 5 fibrocellular crescents, as well as the fibrinoid necrosis lesions upon light microscopy. This indicates our patient might be at the relatively early stage of crescentic glomerulonephritis and the renal biopsy findings may interpret the better response to immunosuppressive treatments in our case.

Concerning the prognosis of this group of patients, Nasr SH et al. reported that 50% of patients had reached endpoints of end-stage renal stage (ESRD) or death whether or not treated with immunosuppressive agents and the only independent predictor of progression to ESRD was serum creatinine at biopsy.5 However, the different outcomes of the two cases we and Dr. Gioacchino Li Cavoli exhibited reveal that the histological finding is more reliable to predict the prognosis. As Dr. Gioacchino Li Cavoli mentioned in the comment, the importance of recognizing the patients with membranous nephropathy and crescentic glomerulonephritis at early stage of the disease is that early immunosuppressive treatment may ameliorate the progression of renal damage and may contribute to the useful recovery of renal function.

Watanabe S et al. demonstrated that the patient had MPO-ANCA-associated glomerulonephritis superimposed on idiopathic membranous nephropathy in the coexistence of MGN and ANCA-associated glomerulonephritis.6 It is well recognized that ANCA-positive patient may develop ANCA-related crescentic glomerulonephritis; however, the immunopathogenesis of crescentic transformation in ANCA-negative patients with primary membranous nephropathy seemed to be more difficult to elucidate. Whether there are some other undetected autoantibodies involved in the pathogenesis of MGN accompanied by ANCA-negative crescentic glomerulonephritis remains unclear. Therefore, further research is required to clarify the pathogenesis of this rare concomitance and investigate the optimum treatment regimes for it.

 

Conflict of interest

 

The authors declare that there is no conflict of interest associated with this manuscript.

Bibliography
[1]
Kwan JT, Moore RH, Dodd SM, Cunningham J. Crescentic transformation in primary membranous glomerulonephritis. Postgrad Med J 1991;67:574-6. [Pubmed]
[2]
Taniguchi Y, Yorioka N, Kumagai J, Ito T, Yamakido M, Taguchi T. Myeloperoxidase antineutrophil cytoplasmic antibody-positive necrotizing crescentic glomerulonephritis and membranous glomerulonephropathy. Clin Nephrol 1999;52:253-5. [Pubmed]
[3]
Zhou GY. Membranous glomerulonephritis associated with myeloperoxidase anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. Nefrologia 2012;32(4):548-51. [Pubmed]
[4]
Kanahara K, Yorioka N, Nakamura C, Kyuden Y, Ogata S, Taguchi T, et al. Myeloperoxidase-antineutrophil cytoplasmic antibody-associated glomerulonephritis with membranous nephropathy in remission. Intern Med 1997;36:841-6. [Pubmed]
[5]
Nasr SH, Said SM, Valeri AM, Stokes MB, Masani NN, D'Agati VD, et al. Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis. Clin J Am Soc Nephrol 2009;4:299-308. [Pubmed]
[6]
Watanabe S, Arimura Y, Nomura K, Kawashima S, Yoshihara K, Kaname S, et al. [Case of MPO-ANCA-associated vasculitis with membranous nephropathy]. Nihon Jinzo Gakkai Shi 2011;53:46-52. [Pubmed]
Download PDF
Idiomas
Nefrología (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?